Daniel F Hayes

List of Publications by Year
in descending order

138 papers	23,435 citations	28274 55 h-index	12597 132 g-index
142 all docs	142 docs citations	142 times ranked	25263 citing authors

#	Article	IF	Citations
1	Osteonecrosis of the jaw risk factors in bisphosphonateâ€treated patients with metastatic cancer. Oral Diseases, 2022, 28, 193-201.	3.0	7
2	A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptorâ€“positive Breast Cancer, SWOG S1222. Clinical Cancer Research, 2022, 28, 611-617.	7.0	4
3	Muscle Mass Affects Paclitaxel Systemic Exposure and May Inform Personalized Paclitaxel Dosing. British Journal of Clinical Pharmacology, 2022, , .	2.4	2
4	Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. Journal of Clinical Oncology, 2022, 40, 1721-1731.	1.6	8
5	Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. Npj Breast Cancer, 2022, 8, 31.	5.2	7
6	Serial monitoring of genomic alterations in circulating tumor cells of ERâ€positive/HER2â€negative advanced breast cancer: feasibility of precision oncology biomarker detection. Molecular Oncology, 2022, 16, 1969-1985.	4.6	8
7	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369.	5.5	18
8	Ki67 as a Companion Diagnostic: Good or Bad News?. Journal of Clinical Oncology, 2022, 40, 3796-3799.	1.6	10
9	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Journal of the National Cancer Institute, 2021, 113, 390-399.	6.3	62
10	Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. Journal of Clinical Oncology, 2021, 39, 238-248.	1.6	49
11	Inertial focusing of circulating tumor cells in whole blood at high flow rates using the microfluidic CTCKeyâ„¢ device for CTC enrichment. Lab on A Chip, 2021, 21, 3559-3572.	6.0	25
12	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncology, 2021, 7, 525-533.	7.1	65
13	Response to Zhang and Yang. Journal of the National Cancer Institute, 2021, 113, 1597-1598.	6.3	4
14	Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. Npj Breast Cancer, 2021, 7, 77.	5.2	16
15	Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. Pharmacogenetics and Genomics, 2021, 31, 116-123.	1.5	4
16	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptorâ€“Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. Clinical Cancer Research, 2021, 27, 6115-6123.	7.0	9
17	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2021, 113, 808-819.	6.3	319
18	PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS ONE, 2021, 16, e0260124.	2.5	26

#	Article	IF	Citations
19	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 2021, 385, 2336-2347.	27.0	363
20	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. Journal of the National Cancer Institute, 2020, 112, 698-707.	6.3	48
21	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	7.1	51
22	Completing the Translation. Oncologist, 2020, 25, 183-185.	3.7	0
23	Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells. Frontiers in Endocrinology, 2020, 11, 35.	3.5	24
24	Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival. British Journal of Cancer, 2020, 122, 801-811.	6.4	52
25	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology, 2020, 38, 1346-1366.	1.6	673
26	Clinical Applications of Circulating Tumor Cells in Breast Cancer. Recent Results in Cancer Research, 2020, 215, 147-160.	1.8	8
27	Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).. Journal of Clinical Oncology, 2020, 38, 1001-1001.	1.6	40
28	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Modern Pathology, 2019, 32, 59-69.	5.5	78
29	Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole. Pharmacogenomics, 2019, 20, 571-580.	1.3	7
30	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
31	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€“Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
32	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	27.0	349
33	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology, 2019, 75, 225-235.	2.9	74
34	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. New England Journal of Medicine, 2019, 380, 1226-1234.	27.0	95
35	A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells. Nature Communications, 2019, 10, 1478.	12.8	80
36	Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion. Breast Cancer Research and Treatment, 2019, 175, 297-303.	2.5	3

#	Article	IF	Citations
37	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. Clinical Cancer Research, 2019, 25, 6089-6097.	7.0	46
38	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253.	2.5	120
39	Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial. Molecular Cancer Therapeutics, 2018, 17, 1324-1331.	4.1	65
40	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. Cancer Research, 2018, 78, 1110-1122.	0.9	85
41	Precision Medicine and Testing for Tumor Biomarkersâ€"Are All Tests Born Equal?. JAMA Oncology, 2018, 4, 773.	7.1	17
42	Disseminated breast tumour cells: biological and clinical meaning. Nature Reviews Clinical Oncology, 2018, 15, 129-131.	27.6	42
43	Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. Journal of Clinical Oncology, 2018, 36, 617-623.	1.6	18
44	Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641.	1.6	668
45	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. Npj Breast Cancer, 2018, 4, 40.	5.2	36
46	Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Research and Treatment, 2018, 171, 657-666.	2.5	34
47	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. Clinical Cancer Research, 2018, 24, 5860-5872.	7.0	44
48	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2018, 379, 111-121.	27.0	1,558
49	Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation. Clinical Breast Cancer, 2017, 17, 350-355.e4.	2.4	10
50	Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer. Breast Cancer Research and Treatment, 2017, 161, 453-461.	2.5	8
51	Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer. Npj Breast Cancer, 2017, 3, 29.	5.2	45
52	Integrative clinical genomics of metastatic cancer. Nature, 2017, 548, 297-303.	27.8	685
53	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 2017, 377, 1836-1846.	27.0	1,052
54	Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Research and Treatment, 2017, 165, 659-668.	2.5	7

#	Article	IF	Citations
55	Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5687-5695.	7.0	170
56	Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors. Breast Cancer Research and Treatment, 2017, 164, 411-419.	2.5	10
57	Delivery of Personalized Medicine With Precision. JCO Precision Oncology, 2017, 1, 1-3.	3.0	0
58	Learning From Our Patients. JCO Clinical Cancer Informatics, 2017, 1, 1-3.	2.1	0
59	American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. Journal of Clinical Oncology, 2017, 35, 2576-2579.	1.6	41
60	Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 292-296.	3.8	7
61	Innovations in American Society of Clinical Oncology Practice Guideline Development. Journal of Clinical Oncology, 2016, 34, 3213-3220.	1.6	14
62	Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226. British Journal of Clinical Pharmacology, 2016, 81, 1134-1141.	2.4	13
63	ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors. Physiological Genomics, 2016, 48, 688-698.	2.3	9
64	Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer. Clinical Cancer Research, 2016, 22, 5864-5875.	7.0	99
65	Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance. Molecular Oncology, 2016, 10, 1078-1085.	4.6	43
66	Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes. Clinical Biochemistry, 2016, 49, 1354-1360.	1.9	175
67	Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. Journal of Clinical Oncology, 2016, 34, 3796-3802.	1.6	29
68	Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622. Breast Cancer Research and Treatment, 2016, 159, 87-95.	2.5	35
69	Is Breast Cancer a Curable Disease?. Journal of Oncology Practice, 2016, 12, 13-16.	2.5	6
70	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. Nature Communications, 2016, 7, 12791.	12.8	196
71	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. Npj Breast Cancer, 2016, 2, 16014.	5.2	109
72	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2016, 12, 384-389.	2.5	42

#	Article	IF	Citations
73	Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2016, 882, 235-258.	1.6	69
74	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 1134-1150.	1.6	683
75	Clinical predictors of long-term survival in HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 155, 589-595.	2.5	34
76	Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clinical Cancer Research, 2015, 21, 2771-2779.	7.0	78
77	Biomarker validation and testing. Molecular Oncology, 2015, 9, 960-966.	4.6	109
78	Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2015, 33, 2695-2704.	1.6	279
79	Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer. Breast Cancer Research and Treatment, 2015, 152, 163-172.	2.5	23
80	An international study to increase concordance in Ki67 scoring. Modern Pathology, 2015, 28, 778-786.	5.5	195
81	Genome Medicine in Cancer: What's in a Name?. Cancer Research, 2015, 75, 1930-1935.	0.9	16
82	Genotyping concordance in DNA extracted from formalinâ€fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Molecular Oncology, 2015, 9, 1868-1876.	4.6	29
83	Reply to F.-C. Bidard et al. Journal of Clinical Oncology, 2015, 33, 1623-1623.	1.6	1
84	Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. Breast, 2015, 24, S6-S10.	2.2	13
85	Neoadjuvant Chemotherapy: What Are the Benefits for the Patient and for the Investigator?. Journal of the National Cancer Institute Monographs, 2015, 2015, 36-39.	2.1	35
86	Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast Cancer Research and Treatment, 2015, 154, 263-273.	2.5	27
87	Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2015, 21, 2487-2498.	7.0	112
88	Promoting Quality and Evidence-Based Care in Early-Stage Breast Cancer Follow-up. Journal of the National Cancer Institute, 2014, 106, dju034-dju034.	6.3	47
89	Molecular Testing in Breast Cancer. Annual Review of Medicine, 2014, 65, 95-110.	12.2	47
90	Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. Journal of Clinical Oncology, 2014, 32, 3483-3489.	1.6	543

#	Article	IF	Citations
91	Effect of Estrogen Depletion on Pain Sensitivity in Aromatase Inhibitorâ€"Treated Women With Early-Stage Breast Cancer. Journal of Pain, 2014, 15, 468-475.	1.4	28
92	Pretreatment worry and neurocognitive responses in women with breast cancer.. Health Psychology, 2014, 33, 222-231.	1.6	62
93	An International Ki67 Reproducibility Study. Journal of the National Cancer Institute, 2013, 105, 1897-1906.	6.3	498
94	Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nature Nanotechnology, 2013, 8, 735-741.	31.5	487
95	Monitoring apoptosis and Bclâ€2 on circulating tumor cells in patients with metastatic breast cancer. Molecular Oncology, 2013, 7, 680-692.	4.6	82
96	From genome to bedside: Are we lost in translation?. Breast, 2013, 22, S22-S26.	2.2	13
97	Breaking a Vicious Cycle. Science Translational Medicine, 2013, 5, 196cm6.	12.4	112
98	OMICS-based personalized oncology: if it is worth doing, it is worth doing well!. BMC Medicine, 2013, 11, 221.	5.5	18
99	Targeting Adjuvant Chemotherapy: A Good Idea That Needs to Be Proven!. Journal of Clinical Oncology, 2012, 30, 1264-1267.	1.6	59
100	Publication of Tumor Marker Research Results: The Necessity for Complete and Transparent Reporting. Journal of Clinical Oncology, 2012, 30, 4223-4232.	1.6	173
101	Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer. New England Journal of Medicine, 2012, 367, 435-444.	27.0	352
102	Biospecimen Reporting for Improved Study Quality. Biopreservation and Biobanking, 2011, 9, 57-70.	1.0	106
103	Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2011, 103, 1656-1664.	6.3	1,505
104	Biomarker studies: a call for a comprehensive biomarker study registry. Nature Reviews Clinical Oncology, 2011, 8, 171-176.	27.6	106
105	Disease related indicators for a proper choice of adjuvant treatments. Breast, 2011, 20, S162-S164.	2.2	1
106	Steady Progress against HER2-Positive Breast Cancer. New England Journal of Medicine, 2011, 365, 1336-1338.	27.0	14
107	Bevacizumab Treatment for Solid Tumors. JAMA - Journal of the American Medical Association, 2011, 305, 506.	7.4	51
108	Response: Re: Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. Journal of the National Cancer Institute, 2011, 103, 1559-1560.	6.3	2

#	Article	IF	Citations
109	Predictive and prognostic markers in cancer. Clinical Advances in Hematology and Oncology, 2011, 9, 130-2.	0.3	1
110	Circulating Tumor Cells. Progress in Molecular Biology and Translational Science, 2010, 95, 95-112.	1.7	37
111	Contribution of biomarkers to personalized medicine. Breast Cancer Research, 2010, 12, S3.	5.0	18
112	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 907-922.	2.5	697
113	Cyclin E as a prognostic factor: What is the question?. Cell Cycle, 2009, 8, 965-965.	2.6	1
114	Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. Journal of the National Cancer Institute, 2009, 101, 1446-1452.	6.3	899
115	Is there a standard type and duration of adjuvant chemotherapy for early stage breast cancer?. Breast, 2009, 18, S131-S134.	2.2	4
116	Cost-effective analyses in Breast Cancer Research and Treatment. Breast Cancer Research and Treatment, 2009, 115, 221-222.	2.5	1
117	Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Research and Treatment, 2008, 111, 365-372.	2.5	200
118	Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?. Clinical Cancer Research, 2008, 14, 3646-3650.	7.0	104
119	Markers of endocrine sensitivity. Breast Cancer Research, 2008, 10, S18.	5.0	7
120	HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. New England Journal of Medicine, 2007, 357, 1496-1506.	27.0	531
121	Follow-up of Patients with Early Breast Cancer. New England Journal of Medicine, 2007, 356, 2505-2513.	27.0	83
122	Angiogenesis as targeted breast cancer therapy. Breast, 2007, 16, 17-19.	2.2	45
123	Adjuvant Systemic Therapy for Elderly Women with Breast Cancer. Women's Health, 2006, 2, 75-87.	1.5	0
124	Uses and Abuses of Tumor Markers in the Diagnosis, Monitoring, and Treatment of Primary and Metastatic Breast Cancer. Oncologist, 2006, 11, 541-552.	3.7	132
125	Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival. Clinical Cancer Research, 2006, 12, 4218-4224.	7.0	937
126	Prognostic and predictive factors revisited. Breast, 2005, 14, 493-499.	2.2	93

#	Article	IF	Citations
127	RESPONSE: Re: Playing the Old Piano: Another Tune for Endocrine Therapy. Journal of the National Cancer Institute, 2004, 96, 557-557.	6.3	0
128	Tamoxifen: Dr. Jekyll and Mr. Hyde?. Journal of the National Cancer Institute, 2004, 96, 895-897.	6.3	24
129	Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer. New England Journal of Medicine, 2004, 351, 781-791.	27.0	4,124
130	Markers of increased risk for failure of adjuvant therapies. Breast, 2003, 12, 543-549.	2.2	17
131	c-erbB-2 in breast cancer: Development of a clinically useful marker. Seminars in Oncology, 2002, 29, 231-245.	2.2	119
132	2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*. Journal of Clinical Oncology, 2001, 19, 1865-1878.	1.6	770
133	The role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer, 2001, 8, 171-183.	2.9	32
134	Prognostic factors in breast cancer: current and new predictors of metastasis. Journal of Mammary Gland Biology and Neoplasia, 2001, 6, 375-392.	2.7	184
135	Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2000, 18, 2710-2717.	1.6	108
136	Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Research and Treatment, 1998, 52, 239-259.	2.5	74
137	Circulating Tumor Markers in Breast Cancer. Hematology/Oncology Clinics of North America, 1989, 3, 653-674.	2.2	27
138	Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Breast Cancer. Journal of Clinical Oncology, 0, , .	1.6	0